Endometriosis: What Women Need to Know

Endometriosis is a chronic gynecological condition in which tissue similar to the uterine lining grows outside the uterus, triggering inflammation, scarring, and pain that can significantly impair quality of life and fertility. The condition affects an estimated 1 in 10 people assigned female at birth during reproductive years, according to the World Health Organization, translating to approximately 190 million individuals worldwide. This page covers the condition's definition, underlying mechanisms, causal drivers, classification system, clinical tradeoffs, and documented misconceptions — drawing on named public health sources throughout.

Definition and scope

Endometriosis imposes a measurable burden on reproductive health, workplace productivity, and healthcare systems. The Office on Women's Health (OWH), a division of the U.S. Department of Health and Human Services, identifies endometriosis as one of the most common gynecological conditions seen in clinical practice, yet one of the most underdiagnosed. The average delay between symptom onset and confirmed diagnosis has been documented in peer-reviewed literature at 7 to 10 years, a gap attributed to symptom normalization, clinician variability, and the requirement for surgical confirmation.

Lesions — sometimes called implants — are most frequently found on the ovaries, fallopian tubes, the outer surface of the uterus, and the tissue lining the pelvis. Less commonly, lesions appear on the bowel, bladder, rectum, and, in rare cases, distant sites including the diaphragm or lungs. The condition is estrogen-dependent, meaning lesion activity typically corresponds to hormonal fluctuations across the menstrual cycle. As a reproductive health concern with systemic implications, endometriosis intersects with conditions including polycystic ovary syndrome, ovarian cysts, and fertility challenges.

Core mechanics or structure

Endometrial-like tissue outside the uterus responds to the same hormonal signals — primarily estrogen and progesterone — that govern the normal menstrual cycle. Each cycle causes this ectopic tissue to thicken, break down, and bleed. Unlike the endometrium inside the uterus, which exits the body during menstruation, blood and tissue from ectopic lesions have no exit route, causing local inflammation and eventual scar formation.

The inflammatory cascade involves immune mediators including prostaglandins and cytokines. Over repeated cycles, this chronic inflammation produces fibrous adhesions — bands of scar tissue that can bind adjacent organs together. On the ovaries, accumulated blood from lesions forms structures called endometriomas, colloquially referred to as "chocolate cysts" due to their dark-colored contents. The National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health, notes that nerve fiber infiltration within lesions is a key mechanism underlying the condition's characteristic pain patterns, which can include dysmenorrhea (painful periods), dyspareunia (pain during intercourse), and chronic pelvic pain.

Neuroangiogenesis — the concurrent growth of nerves and blood vessels into lesion tissue — is an active area of investigation because it explains why pain severity does not correlate predictably with lesion size or number. Small lesions with dense nerve supply can produce severe pain, while large endometriomas may cause minimal discomfort.

Causal relationships or drivers

No single cause of endometriosis has been established. The dominant mechanistic hypothesis, retrograde menstruation, proposes that menstrual blood flows backward through the fallopian tubes into the pelvic cavity, depositing endometrial cells that subsequently implant and proliferate. First described by Dr. John Sampson in the 1920s, this theory does not fully explain all cases because retrograde menstruation occurs in an estimated 90% of people who menstruate, yet only a fraction develop endometriosis, suggesting additional factors govern implantation.

Genetic predisposition is well-documented. First-degree relatives of individuals with endometriosis carry a 7- to 10-fold increased risk compared to the general population, per data cited by the American College of Obstetricians and Gynecologists (ACOG). Immune dysregulation is a secondary driver — specifically, impaired natural killer cell activity that fails to clear ectopic endometrial tissue from the pelvic cavity. Environmental exposures, particularly to dioxins and polychlorinated biphenyls (PCBs), have been investigated by the National Institute of Environmental Health Sciences (NIEHS) as potential contributors to immune modulation, though causation in human populations has not been conclusively established.

Coelomic metaplasia — the transformation of peritoneal cells into endometrial-like cells — offers an alternative explanation for cases involving distant or unusual lesion sites, including those found before menarche or after menopause.

Classification boundaries

The most widely applied staging system is the revised American Society for Reproductive Medicine (rASRM) classification, which scores endometriosis on a point system from 1 to 150+ based on lesion size, location, depth, and adhesion extent:

The rASRM system, maintained by the American Society for Reproductive Medicine (ASRM), has known limitations: stage does not reliably predict pain severity or fertility outcomes. A separate classification, the Endometriosis Fertility Index (EFI), was developed specifically to estimate postoperative pregnancy probability. A third framework — the ENZIAN classification — describes deeply infiltrating endometriosis (DIE) using an anatomical compartment system and is increasingly referenced in surgical planning contexts.

Deeply infiltrating endometriosis represents a distinct clinical subtype in which lesions penetrate more than 5 millimeters beneath the peritoneal surface and may involve the uterosacral ligaments, vagina, bowel, or bladder — structures outside the scope of superficial implants captured by rASRM staging alone.

Tradeoffs and tensions

Surgical diagnosis versus empirical treatment represents the central clinical tension in endometriosis management. Definitive diagnosis requires laparoscopy with histological confirmation — an invasive procedure carrying anesthesia risk, surgical complication rates, and recovery time. Empirical hormonal treatment (typically combined oral contraceptives or progestin-only therapy) is frequently initiated without surgical confirmation, particularly by the regulatory framework governing off-label prescribing and diagnostic practice standards.

Hormonal suppression can reduce lesion activity and pain but does not eradicate lesions, and symptoms commonly recur after cessation. Surgical excision — considered more definitive than ablation (destruction) of lesions — carries its own recurrence rates: published data from ACOG indicate that up to 40% of patients undergoing conservative surgery experience symptom recurrence within 5 years without adjuvant hormonal therapy.

Fertility preservation creates additional tension. Repeated surgical interventions on ovarian endometriomas risk damage to ovarian reserve, measurable via anti-Müllerian hormone (AMH) levels. Hysterectomy with bilateral salpingo-oophorectomy (BSO) is the most definitive surgical option but permanently ends natural fertility and induces surgical menopause, a transition requiring its own management as outlined in resources covering menopause symptoms and management.

Pain management also involves tradeoffs: long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) carries gastrointestinal risk, while GnRH agonists — which suppress estrogen to near-menopausal levels — can cause bone density loss measurable within 6 months of treatment initiation, as noted by the FDA prescribing information for leuprolide acetate.

Common misconceptions

Misconception: Painful periods are a normal part of menstruation.
Dysmenorrhea severe enough to interfere with daily activities is not a baseline expectation of menstruation. The Office on Women's Health explicitly identifies this conflation as a primary reason patients delay seeking evaluation, contributing to the multi-year diagnostic gap.

Misconception: Endometriosis is confirmed by a blood test or imaging alone.
No blood biomarker or imaging modality currently provides definitive diagnosis. CA-125, a serum marker sometimes elevated in endometriosis, lacks sufficient sensitivity and specificity for diagnostic use according to ACOG. Transvaginal ultrasound can identify endometriomas but misses superficial peritoneal implants and many deeply infiltrating lesions.

Misconception: Pregnancy cures endometriosis.
Pregnancy can temporarily suppress lesion activity through hormonal changes, but it does not eliminate lesions, and symptoms typically return after the postpartum period. The NICHD does not list pregnancy among recognized treatments.

Misconception: Endometriosis affects only reproductive-age women.
Cases have been documented in adolescents as young as 11 and in postmenopausal individuals. While estrogen drives lesion activity, the condition is not confined to the standard reproductive window of approximately ages 15 to 49.

Misconception: Hysterectomy always resolves endometriosis.
If ectopic lesions outside the uterus are not excised at the time of hysterectomy, residual implants can continue to respond to endogenous or exogenous estrogen, resulting in persistent symptoms.

Checklist or steps (non-advisory)

The following represents a structured sequence of documented clinical evaluation steps for endometriosis, as described in ACOG practice guidelines and OWH educational materials. This is a reference sequence, not clinical direction.

  1. Symptom documentation — Record cycle timing, pain location, severity, and impact on function across at least 2 to 3 menstrual cycles
  2. Medical and family history review — Note first-degree relatives with diagnosed endometriosis; identify prior gynecological surgeries or conditions
  3. Pelvic examination — Clinical assessment for tenderness, nodularity, or fixed uterine position consistent with adhesions
  4. Transvaginal ultrasound — Evaluate for endometriomas and structural anomalies; note limitations in detecting superficial lesions
  5. Laboratory evaluation — Rule out other causes of pelvic pain including infection; CA-125 may be ordered but is not diagnostic
  6. Specialist referral — Gynecologist or reproductive endocrinologist evaluation for complex or persistent cases
  7. Laparoscopy with biopsy — Surgical visualization with histological confirmation remains the diagnostic standard
  8. Classification staging — rASRM scoring and, where applicable, ENZIAN classification of deeply infiltrating disease
  9. Treatment pathway determination — Based on stage, fertility goals, symptom burden, and patient history; options include hormonal therapy, surgery, or combined approaches
  10. Long-term monitoring — Reassessment of symptom control, recurrence indicators, and ovarian reserve where surgical intervention has occurred

Additional context on pelvic health and related structural conditions is available through the pelvic floor health reference page. For a broad orientation to women's health topics covered across this resource, the main index provides a structured entry point.

Reference table or matrix

Feature Stage I (Minimal) Stage II (Mild) Stage III (Moderate) Stage IV (Severe)
rASRM Score Range 1–5 6–15 16–40 >40
Lesion Depth Superficial Superficial to moderate Deep (some) Deep (extensive)
Endometriomas Present Rare Possible (<1 cm) Often (≥1 cm) Common (bilateral, large)
Adhesion Extent None to minimal Minor Moderate Dense, organ-binding
Fertility Impact Minimal Mild Moderate Significant
Pain Correlation Weak Weak Variable Variable
Surgical Complexity Low Low–Moderate Moderate–High High
DIE Classification Needed Rarely Rarely Sometimes Frequently

Source: American Society for Reproductive Medicine revised classification system (ASRM).

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)